Select Bibliography

Filter by any of these (after searching):

NCCTG-964251

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 3 items

Use of KW-2189, a DNA minor groove-binding agent, in patients with hepatocellular carcinoma: a north central cancer treatment group (NCCTG) phase II clinical trial.

Alberts, Steven R , Suman, Vera J , Pitot, Henry C ... - - J Gastrointest Cancer - 2007

Manuscript - Primary - Primary - GI - NCCTG-964251

Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales.

Singh, Jasvinder A , Locke, Dona E , Satele, Daniel ... - ASCO - J. Clin. Oncol. - 2014

Abstract - Secondary-not-in-original - Meta-Analysis - Health Outcome - 954651 , NCCTG-95-20-53 , NCCTG-95-24-52 , 959204 , NCCTG-964251 , 979202 , NCCTG-98-24-52 , NCCTG-98-72-51 , NCCTG-98-72-52 , NCCTG-959257 , NCCTG-989251 , NCCTG-969256 , NCCTG-971151 , NCCTG-979251 , NCCTG-979253

Normative data and clinically significant effect sizes for single-item numerical linear analogue self-assessment (LASA) scales

Singh, Jasvinder A , Satele, Daniel , Pattabasavaiah, Suneetha ... - - Health Qual Life Outcomes - 2014

Manuscript - No-Endpoint - Meta-Analysis - Health Outcome - NCCTG-95-20-53 , 954651 , 959204 , NCCTG-95-24-52 , NCCTG-964251 , 979202 , NCCTG-97-24-51 , NCCTG-98-24-52 , NCCTG-98-72-51 , NCCTG-959257 , NCCTG-98-72-52 , NCCTG-989251 , NCCTG-969256 , NCCTG-971151 , NCCTG-979251 , NCCTG-979253